Diagnosis of Idiopathic Environmental Intolerance (IEI)
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and diagnostic testing for idiopathic environmental intolerance (IEI, formerly multiple chemical sensitivity) for Blue Cross Blue Shield of North Carolina members and describes which tests and procedures related to IEI are considered investigational or not reimbursable.
CC7 edited to state breath hydrogen/methane testing is not allowed under any circumstances and now reads: '7. Reimbursement is not allowed for breath hydrogen and/or breath methane testing.'
CC2 and CC3, replaced 'In all circumstances' with 'For asymptomatic individuals and/or during general encounters without abnormal findings' for clarity.
CC4, CC5, CC6, CC8 were edited for consistency.
Removed section titled 'Reimbursement' from the Billing/Coding section.
Coverage Criteria — Diagnosis of IEI
Diagnosis of IEI
Coverage stance
See specific not-covered test list for examples.
Tests not reimbursable for IEI diagnosis
Not covered testing examples
Specific enumerated items listed in policy.
Coverage stance — investigational / not covered
Policy states BCBSNC will not provide coverage for the diagnosis of idiopathic environmental intolerance because it is considered investigational.
From policy history and 'Not Covered' statement
Disallowed diagnostic testing
Certain diagnostic tests explicitly disallowed for reimbursement.
CC7 edited to prohibit breath hydrogen/methane testing
When Diagnosis of Idiopathic Environmental Intolerance is covered: Not applicable.
The American Academy of Allergy, Asthma and Immunology (AAAAI) has advised that many nonvalidated immune-based tests previously used to suggest an immunologic basis for idiopathic environmental intolerance (IEI) are expensive, not useful or valid, and should be discouraged.
Multiple professional societies have expressed skepticism about recognizing IEI (historically called multiple chemical sensitivity) as a distinct syndrome until there are accurate, reproducible, and well-controlled studies. For example, the American Medical Association in 1992 recommended that MCS not be recognized as a syndrome until better evidence is available; similar reservations have been held by the American College of Physicians and other organizations.
Policy history documents a sequence of revisions listing specific laboratory and diagnostic categories that were added or removed over time. The implementation notes record updates to the When Not Covered and Billing/Coding sections as tests and CPT codes were revised during 2019–2021.
Reimbursement is not allowed for screening or profiling tests performed on asymptomatic individuals and/or during general encounters without abnormal findings. Examples enumerated in the policy include screening of blood, saliva, serum, plasma, urine, and stool for volatile solvents, organic acids, organophosphates, phthalates, parabens, chlorinated pesticides (including DDE and DDT), metals, micronutrients, and broader vitamin/mineral/nutritional analyses.
There is insufficient evidence to support routine clinical use of sugar-related breath tests for fructose, sorbitol, trehalose, maltitol, and sucrose. The literature review cited in the policy notes the absence of gold standards and validation studies for many of these carbohydrate breath tests and concludes that blind sugar challenge remains the most valid technique to demonstrate clinical carbohydrate intolerance.
Breath testing has recognized limitations and variable evidence depending on the indication. North American expert consensus suggests breath testing may be useful for assessing small intestinal bacterial overgrowth (SIBO) and for certain carbohydrate maldigestion syndromes, but quality of evidence ranges from low to moderate and standardization is lacking. The consensus recommends testing protocols (for example, performing fructose and lactose breath tests for at least 3 hours) and cautions that interpretation and preparation vary across centers.
BCBSNC considers the diagnosis of idiopathic environmental intolerance (IEI) to be investigational and therefore will not provide coverage for services intended to confirm this diagnosis. The policy explicitly states that tests designed to confirm IEI are not reimbursable and directs readers to the enumerated not-covered items.
Billing and Service Codes
Provider Actions, Authorization, and Documentation
Prior authorization not applicable — tests investigational / not reimbursable
No tests to confirm the diagnosis of idiopathic environmental intolerance (IEI) are covered; reimbursement is not allowed for laboratory tests designed to confirm the diagnosis of IEI in all circumstances. See the policy for specific enumerated sample types and test categories that are not reimbursable.
Applicable service codes (listing does not guarantee reimbursement)
This policy lists applicable service codes that may be associated with testing subject to medical necessity review. Inclusion of a code does not guarantee reimbursement; refer to the group contract and subscriber certificate for benefit determination.
- Applicable service codes: 82108, 82127, 82136, 82139, 82300, 82379, 82380, 82441, 82495, 82507, 82525, 82542, 82653, 82656, 82705, 82710, 82715, 82726, 82978, 83015, 83018, 83150, 83497, 83655, 83735, 83785, 83885, 83918, 83919, 83921, 84134, 84255, 84446, 84585, 84590, 84600, 84630, 86001, 86353, 89125, 91065, S3708
Authorization note — medical policy is not an authorization; verify benefits and eligibility
Medical policy is not an authorization. Verify benefits and eligibility from the group contract and subscriber certificate prior to ordering or billing services; benefits and eligibility are determined before medical guidelines and payment guidelines are applied.
Clinical-first evaluation — begin with history, physical, basic labs and symptom-guided testing
Perform a clinical-first evaluation before pursuing specialized testing: obtain a history and physical exam, perform basic laboratory tests, and use symptom-guided further testing to direct additional evaluations.
- Use occupational/environmental history and screening questionnaires (e.g., EESI) to guide evaluation.
- Screen for psychiatric comorbidity (e.g., PHQ-9) as part of the assessment.
Required clinical evaluation components
An evaluation of patients with suspected IEI must include a detailed history and physical examination and basic laboratory testing; further diagnostic testing should be guided by reported symptoms and clinical findings.
- Include occupational/environmental exposure history and consider use of screening questionnaires (EESI).
- Consider psychiatric history and use PHQ-9 to identify comorbid psychiatric conditions.
Medical record documentation requirement when records are requested
When BCBSNC requests medical records to determine medical necessity, include all specific information needed for the determination; letters of support or explanation alone are not sufficient unless they contain all required clinical details.
- Provide history, physical exam findings, basic laboratory results, symptom-guided test results, and any screening questionnaire results when available.
Benefit determination — verify group contract and subscriber certificate before applying guidelines
Determine benefits and eligibility from the member’s group contract and subscriber certificate prior to applying medical policy guidelines; coverage decisions are made based on those documents at the time services are rendered.
PROVIDER ACTIONS — Reimbursement not allowed for laboratory tests to confirm IEI
Reimbursement is not allowed for laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance in all circumstances; numerous specific sample types and test categories are listed as not reimbursable.
- Not reimbursable sample types include blood, saliva, serum, plasma, urine, stool, hair, fingernails, and cerebrospinal fluid.
- Not reimbursable categories include volatile solvents, organic acids, organophosphates, phthalates, parabens, chlorinated pesticides (including DDE and DDT), metals, micronutrients, vitamin/mineral/nutritional analyses, carnitine, oxidative stress assessments, detoxification/methylation testing, lipoic acid/CoQ10 sufficiency, intestinal hyperpermeability, and profiling panels.
Documentation requests may trigger denials — provide complete records when requested
BCBSNC may request medical records for determination of medical necessity; failure to provide the requested documentation or missing required information can trigger a denial of the service.
Prohibition of breath hydrogen/methane testing — not reimbursable
Reimbursement is not allowed for breath hydrogen and/or breath methane testing; breath hydrogen/methane testing is explicitly prohibited under any circumstances for this diagnosis.
- Policy now reads: 'Reimbursement is not allowed for breath hydrogen and/or breath methane testing.'
Background and Scope
Background: Idiopathic environmental intolerance (IEI), formerly called multiple chemical sensitivity, is a subjective syndrome of recurrent nonspecific symptoms that patients attribute to low-level chemical, biologic, or physical exposures. These symptoms are heterogeneous, common in the general population, and often occur with psychiatric comorbidities. The condition lacks consistent objective diagnostic findings or validated laboratory tests; testing programs for IEI have poor validity and may produce false positives or increase patient anxiety.
Definitions
Policy Revision History
New policy developed stating BCBSNC will not provide coverage for the diagnosis of idiopathic environmental intolerance (IEI) because it is considered investigational; noticed 1/1/2019 for effective date 4/1/2019.
Policy reviewed by Avalon CAB; 'When Not Covered' extensively revised with additions and billing/coding section updated with multiple CPT codes; policy noticed 6/11/2019 for effective date 8/13/2019.
Specialty Matched Consultant Advisory Panel and Medical Director reviews documented (11/2020) and recorded 12/8/2020.
Specialty Matched Consultant Advisory Panel and Medical Director reviews documented (11/2021).
Policy Guidelines updated; Table of Terminology added then later removed in subsequent edits; Billing/Coding codes adjusted (code removals noted).
Off-cycle review and edits to coverage criteria for clarity; updates made to policy guidelines, billing/coding and references; no change to policy statement.
Reviewed by Avalon 1st Quarter 2024 CAB with updates to Description, Policy Guidelines and References; no change to policy statement.
Reviewed by Avalon 4th Quarter 2024 CAB with updates to Description, Policy Guidelines and References; Medical Director review noted 1/2025; no change to policy statement.
Reviewed by Avalon 1st Quarter 2026 CAB; multiple clarity and consistency edits made to coverage criteria including explicit prohibition added: 'Reimbursement is not allowed for breath hydrogen and/or breath methane testing'; Billing/Coding section edit removing the 'Reimbursement' subsection; notification given 2/25/26 for effective date 5/6/26.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.